# Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

> **NCT03134222** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 47 (actual)

## Conditions studied

- Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** Lanraplenib
- **DRUG:** Filgotinib
- **DRUG:** Lanraplenib placebo
- **DRUG:** Filgotinib placebo

## Key facts

- **NCT ID:** NCT03134222
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-24
- **Primary completion:** 2019-03-13
- **Final completion:** 2019-12-18
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03134222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03134222, "Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03134222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*